Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Bud Bilanich
Success Coach

Devin Kanach
Non-Personal Promotion

David Linetsky
Point-of-Care Marketing

Eric Shaffer
Brand Architecture

Adrienne Stevens, EdD, MBA
HCP Insights

Brenda Snow
Authentic Patient Voice

Sarah Caldwell
Data & Analytics

Amy Giles
Increasing Engagement

Ira Haimowitz
Closed-Loop Marketing

Howard Seidman
Patient Acquisition

Chris Dowd
Medication Adherence

Suma Ramadas, PhD
Medical Affairs